🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This study aims to evaluate the efficacy and safety of U3-1402 in participa...
Status
Recruiting
Location
Centre Georges François Leclerc
Start Date
2021-05-11
Trial ID
NCT04965766
Treatments Being Tested
VALENTINE is a parallel, non-comparative, three-arm, randomized 1:2:2 open-...
Status
Active Not Recruiting
Location
ICO Badalona
Start Date
2022-11-25
Trial ID
NCT05569811
Treatments Being Tested
This study includes a Dose Escalation Part to identify the recommended comb...
Status
Active Not Recruiting
Location
UCLA
Start Date
2021-06-11
Trial ID
NCT04676477
Treatments Being Tested
ICARUS-BREAST02 is an open-label, multicenter, phase 1b/2, platform study t...
Status
Recruiting
Location
Gustave Roussy Institut
Start Date
2024-03-21
Trial ID
NCT06298084
Treatments Being Tested
Researchers are looking for other ways to treat breast cancer (BC) that is ...
Status
Recruiting
Location
Southern Cancer Center (SCC) ( Site 8000)
Start Date
2025-07-21
Trial ID
NCT07060807
This is a proof-of-concept study designed to investigate HER3-DXd monothera...
Status
Recruiting
Location
City of Hope
Start Date
2024-02-26
Trial ID
NCT06172478
Treatments Being Tested
The primary purpose of the study is to assess the safety, tolerability, and...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2026-08-03
Trial ID
NCT07701941
Treatments Being Tested
This study was designed to evaluate safety and antitumor activity of HER3-D...
Status
Active Not Recruiting
Location
City of Hope
Start Date
2017-10-30
Trial ID
NCT03260491
Treatments Being Tested
The purpose of this study is to assess the efficacy and safety of pembroliz...
Status
Recruiting
Location
Banner MD Anderson Cancer Center ( Site 0001)
Start Date
2019-12-19
Trial ID
NCT04165070
Activity of patritumab deruxtecan (U3-1402; HER3-DXd) has been shown in a p...
Status
Recruiting
Location
Antoni van Leeuwenhoek
Start Date
2025-03-03
Trial ID
NCT06222489
Treatments Being Tested